Psimei Pharmaceuticals plc is a leader in the development of Boron Cellular Radiotherapy (BCR) based products, designed to significantly improve the clinical effectiveness of radiotherapy in the treatment of cancer. At present only 30% of cancer patients receiving radiotherapy are "cured" equating to complete clinical responses for up to 5 years.
Psimei is currently pursuing two approaches to BCR. These are based on boron containing agents, which can be activated by standard radiotherapy equipment (Photon Activation Technology - PAT) and by low energy neutrons (Boron Neutron Capture Technology - BNCT). The company is also working to define the therapeutic potential of the PAT and BNCT platforms in the wider field of medicine, outside cancer. In addition, a portfolio of new technologies is under investigation for the treatment of other serious diseases.
Psimei Pharmaceuticals plc's product development and commercial strategy is expected to deliver significant value to its shareholders based on its core principles of robust science, targeting clearly defined market needs, realistic development plans and sound financial management.
Follow the links below to find out more:
profile.html
technology.html
people.html
licensing.html
news.html
contact.html
If you are unable to view our website or would like to request more information please email us at corporateaffairs@psimei.com
Thankyou for visiting the Psimei Pharmaceuticals plc website.